Signaling pathways and mesenchymal transition in pediatric high-grade glioma

Michaël H. Meel1 · Sophie A. Schaper1 · Gertjan J. L. Kaspers1,2 · Esther Hulleman1

Received: 28 August 2017 / Revised: 24 October 2017 / Accepted: 14 November 2017 / Published online: 21 November 2017 © The Author(s) 2017. This article is an open access publication

Abstract
Pediatric high-grade gliomas (pHGG), including diffuse intrinsic pontine gliomas (DIPG), are the most lethal types of cancer in children. In recent years, it has become evident that these tumors are driven by epigenetic events, mainly mutations involving genes encoding Histone 3, setting them apart from their adult counterparts. These tumors are exceptionally resistant to chemotherapy and respond only temporally to radiotherapy. Moreover, their delicate location and diffuse growth pattern make complete surgical resection impossible. In many other forms of cancer, chemo- and radioresistance, in combination with a diffuse, invasive phenotype, are associated with a transcriptional program termed the epithelial-to-mesenchymal transition (EMT). Activation of this program allows cancer cells to survive individually, invade surrounding tissues and metastasize. It also enables them to survive exposure to cytotoxic therapy, including chemotherapeutic drugs and radiation. We here suggest that EMT plays an important, yet poorly understood role in the biology and therapy resistance of pHGG and DIPG. This review summarizes the current knowledge on the major signal transduction pathways and transcription factors involved in the epithelial-to-mesenchymal transition in cancer in general and in pediatric HGG and DIPG in particular. Despite the fact that the mesenchymal transition has not yet been specifically studied in pHGG and DIPG, activation of pathways and high levels of transcription factors involved in EMT have been described. We conclude that the mesenchymal transition is likely to be an important element of the biology of pHGG and DIPG and warrants further investigation for the development of novel therapeutics.

Keywords High-grade glioma · Diffuse intrinsic pontine glioma · Epithelial-to-mesenchymal transition · Glioblastoma · Chemo- and radioresistance

Introduction
Brain tumor is the number one cause of cancer-related morbidity and mortality in children and adolescents. Among pediatric brain tumors, high-grade gliomas (HGG), and especially, diffuse intrinsic pontine gliomas (DIPG) carry the worst prognosis with a 5-year survival of less than 10% [1]. For DIPG, median survival is only 11 months [2]. On a molecular level, DIPG is characterized by a high prevalence of mutations in genes encoding Histone 3 (mainly H3F3A and HIST1H3B), leading to a lysine-to-methionine substitution at position 27 in the N-terminal tail of the histone protein, causing global H3K27 hypomethylation. Supratentorial pHGG often carry a G34R/V mutation in H3F3A, resulting in decreased H3K36 methylation [3–7]. These mutations set the pediatric brain tumors apart from their adult counterparts, and emphasize the necessity to research them independently. Given the highly infiltrative nature and delicate location of DIPG in the brainstem, surgery is generally impossible. Historically, the diagnosis of DIPG was based on MRI appearance of the tumor, and surgical biopsies were rarely performed. However, in recent years, many institutes are re-introducing biopsies in early clinical phase studies to enable molecular characterization of the tumor [8]. In contrast, supratentorial pHGG is almost always subjected to surgery. Although rarely resulting in a cure of the patient, the extent of surgical resection is one of the most important
independent clinical prognostic factors [9]. Additionally, pediatric HGG and DIPG are extremely chemoresistant, partially due to the blood–brain barrier (BBB) and partially due to intrinsic factors [10]. To this day, no chemotherapy regimen is known to produce any response in DIPG at acceptable toxicity levels, and only a very modest survival benefit of chemotherapy is seen in supratentorial pediatric HGG [9]. The only treatment that definitively benefits patients with pHGG and DIPG is intensive radiotherapy, which alleviates symptoms and slightly prolongs survival, but offers no chance for a cure. In adult glioblastoma (GBM), as in other types of cancer, the intrinsic chemoresistance has been related to the process of epithelial-to-mesenchymal transition (EMT), a transcriptional process in which epithelial cells adopt mesenchymal properties by loss of cell–cell adhesion, acquisition of migratory and invasive properties and loss of cell polarity [11, 12]. In tumors, in general, EMT contributes to initiation, invasion, metastasis to distant sites and resistance to chemo- and/or radiotherapy. Additionally, it is believed to stimulate the development and maintenance of a cancer stem cell (CSC) population within the tumor [13–15]. We hypothesize that EMT plays an equally important role in pediatric HGG and DIPG, by which it would be responsible for the intrinsic chemoresistance and diffuse nature of these tumors.

EMT is induced by external factors, such as cytokines, growth factors and hypoxia. Different signaling pathways lead to activation of EMT transcription factors; most importantly SNAI1 (SNAIL), SNAI2 (SLUG), ZEB1, ZEB2 and TWIST. These transcription factors inhibit the expression of genes that promote cell–cell contact, most importantly E-cadherin, and induce genes that promote migration and stemness [11, 16–18]. This review serves to summarize current knowledge on the process of mesenchymal transition in pediatric HGG and DIPG.

**Transcription factors involved in the mesenchymal transition**

**SNAIL family of transcription factors**

One of the most important regulators of the mesenchymal transition is the SNAIL family of master transcriptional regulators, consisting of three members; SNAIL (SNAI1), SLUG (SNAI2) and SMUC (SNAI3). SNAIL family transcription factors are basic zinc finger transcription factors with a broad variety of functions during normal development and cancer progression [19–22]. Most research has been dedicated to unraveling the role of these factors in the epithelial-to-mesenchymal transition. Central to this role is their ability to repress E-cadherin transcription through direct binding to the CDH1 promoter and concurrently increase the expression of other cadherins, such as N-cadherin (CDH2) [11, 23]. Furthermore, SNAIL transcription factors have a profound impact on epigenetic regulation of transcription through recruitment of several histone methyltransferases, demethylases, acetyltransferases and deacetylases to the histone-DNA complex, thus resulting in the transcription of genes associated with a mesenchymal phenotype and concurrent repression of epithelial genes, such as occludins, claudins, mucins and cytokeratins [24, 25] (Fig. 1).

Among the most important mesenchymal proteins are vimentin, fibronectin and matrix metalloproteinases [19]. These proteins are involved in the structural integrity of mesenchymal cells, both through integrin signaling and their capacity to modify the extracellular environment [26, 27]. In cancer progression, this expression of mesenchymal genes [28] allows cancer cells to become less dependent of cell–cell interactions, enabling them to migrate, invade surrounding tissues and eventually metastasize [20, 29–32]. Additionally, SNAIL upregulates the expression of ZEB1, another master transcriptional regulator of the mesenchymal transition [33]. Finally, an important role for these transcription factors lies in their ability to render cancer cells resistant to therapy via incompletely understood mechanisms, as is the case for example in cisplatin-resistant NSCLC, and especially relevant for the current review, GBM [12, 19, 20]. Importantly, SNAIL is found to be a key player in mesenchymal transition in malignant gliomas, including DIPG, increasing invasion migration, focal adhesion and proliferation [34–38]. SNAIL levels increase after irradiation [34] and its expression is correlated with tumor grade and survival [39]. Although SLUG is not as extensively studied in gliomas as SNAIL, it too is correlated with invasion, histological grade and glioblastoma growth [40].
ZEB family of transcription factors

Another group of master regulators of the mesenchymal transition is the ZEB family of transcription factors, comprising ZEB1 and ZEB2. These transcription factors contain two zinc finger domains which allow DNA binding at E-boxes within the promoter regions of target genes such as E-cadherin and N-cadherin [11]. Whether ZEB1 and ZEB2 function as transcriptional activators or repressors is determined by their interaction with cofactors, such as the Smad family of signal transduction proteins, and other transcription factors. The net result of ZEB activity, however, is always a skewing of gene expression to a more mesenchymal phenotype [41]. Overexpression of ZEB1 and ZEB2 is a common phenomenon in many types of cancer, where it is associated with the maintenance of a cancer stem cell phenotype as well as metastasis and therapy resistance, such as paclitaxel resistance in breast cancer cells [42–44]. ZEB1 has been found to be correlated to a highly infiltrative tumor phenotype in both adult and pediatric high-grade glioma, partially in relation to hypoxia [45, 46]. Moreover, ZEB1 expression is linked to poor temozolomide response and a shorter survival of GBM patients [45]. Interestingly, ZEB1 has been shown to be important for EMT in HGG driven by PDGFRα activation [47]. As pediatric HGG commonly possesses PDGFRα overexpression and activation, this ZEB1-PDGFRα axis may well be important for the mesenchymal transition of pHGG [38, 48–50]. Although less well studied, ZEB2 expression also appears to be correlated with tumor grade and mesenchymal properties in high-grade gliomas [51]. Specific data on the role of ZEB2 in pediatric HGG and DIPG is lacking.

TWIST family of transcription factors

A third group of master regulators of the mesenchymal transition is the TWIST family of basic helix-loop-helix (bHLH) transcription factors, of which TWIST1 and TWIST2 have been studied most. Basic HLH transcription factors, such as the zinc finger transcription factors, exert their action through binding to the E-boxes in the promotor regions of target genes. In this manner, as with the SNAIL and ZEB families of transcription factors, TWIST represses E-cadherin and enhances N-cadherin expression, thereby promoting tumor cell migration, invasion, metastasis and chemoresistance in a broad variety of cancer types [52–55]. TWIST1 has been repeatedly investigated in adult glioma, in which its expression is correlated with higher tumor grade and poorer survival of patients. Mechanistically, this is attributed to the increased migratory and invasive capacities of glioma cells by TWIST1 activity [56]. Additionally, TWIST1 expression has been associated with resistance of glioblastoma cells to temozolomide [57]. Importantly, one study found that a reduction of TWIST1 expression in glioma stem cells, achieved by co-culturing these stem cells with mesenchymal stem cells, induces a mesenchymal-to-epithelial transition (MET), the inverse process of EMT, in these cells [58]. Specific data on the role of TWIST in pediatric HGG and DIPG is not available.

SIX family of transcription factors

Less well studied, but nonetheless relevant, is the SIX family of homeobox transcription factors, of which only SIX1 has received considerable attention. These transcription factors are highly expressed in embryogenesis, where they have an important role in embryonal progenitor cell proliferation and survival. When SIX proteins are aberrantly expressed in non-embryonal tissue they can function as oncogenes, promoting cell proliferation and metastasis in various cancer types, partially through activation of the TGF-β and RAS/MAPK pathways [59–63]. SIX1 has mostly been studied in breast cancer, where it correlates with worse patient survival and induces EMT in cancer stem cells, thereby causing malignant progression [61, 64]. Furthermore, SIX1 has been shown to play a role in EMT in high-grade glioma cells, resulting in increased cell invasiveness [65, 66]. To date, no research has addressed the role of the SIX transcription factors in pediatric HGG or DIPG.

External initiation of the epithelial-to-mesenchymal transition

The epithelial-to-mesenchymal transition is commonly initiated by external stimuli, such as growth factors, cytokines and/or hypoxia. These external stimuli trigger intracellular signaling cascades that ultimately result in an upregulation of transcriptional regulators, such as SNAIL and ZEB [11]. Key pathways in this process include TGFβ and activin signaling, WNT signaling, JAK/STAT, RTK and SHH signaling (Fig. 2).
and phosphorylate SMAD4 [11, 67] (Fig. 2). This trimeric complex translocates to the nucleus, where it both causes expression of and interacts with transcription factors capable of inducing EMT, such as SNAIL, SLUG, ZEB1 and ZEB2 [11]. Furthermore, activation of TGF-β receptors by their ligands can activate canonical signaling pathways such as the PI3K/AKT, MAPK and JNK pathways, which will be discussed later on [68, 69].

In pediatric high-grade glioma, a special role seems to be reserved for the activins within the TGF-β superfamily of proteins. Recent studies have identified activating mutations gene encoding Activin Receptor Type 1 (ACVR1) in a subset of diffuse midline gliomas [50, 70, 71]. Mutations in this gene are known to cause ligand-independent receptor activation with subsequent phosphorylation and nuclear translocation of SMAD1, SMAD 5 and SMAD8 [70, 72–74]. There, they too form a complex with SMAD4 to function as a transcription factor regulating expression of genes inducing EMT [74]. As with many proteins involved in EMT, ACVR1 seems to be mainly involved in embryogenesis under normal circumstances [73]. This observation raises the possibility that ACVR1 mutations induce the mesenchymal transition in diffuse midline gliomas. This hypothesis is supported by the observation that ACVR1 mutations are associated with a mesenchymal gene expression profile in diffuse intrinsic pontine glioma [38]. This makes both ACVR1 and its downstream effectors interesting targets for the treatment of diffuse intrinsic pontine gliomas, especially when combined with other therapeutic modalities.

**WNT signaling in the mesenchymal transition**

In the canonical WNT/β-catenin pathway, WNT first binds to Frizzled cell surface receptors and low-density lipoprotein-related receptor proteins 5 or 6 [75–78]. The activation of Frizzled receptors results in phosphorylation of AKT, followed by inhibitory phosphorylation of GSK3β, resulting in stabilization of SNAIL protein [11]. Moreover, GSK3β inhibition enables β-catenin to act as a transcription factor. Normally, GSK3β is part of a complex with the proteins APC and AXIN, the so-called destruction complex. This complex phosphorylates and thereby degrades β-catenin [79, 80]. Therefore, when GSK3β is inhibited, β-catenin accumulates in the cytoplasm and translocates to the nucleus [81, 82]. There, it serves as a subunit of a high-mobility group (HMG) box transcription factor complex. In association with TCF/LEF, β-catenin induces the expression of genes encoding EMT transcription factors [83, 84]. In addition, β-catenin is an important part of the E-cadherin/β-catenin complex that regulates cellular adhesion and migration, making the WNT/β-catenin pathway a key mechanism regulating EMT in cancer (stem) cells [13].

The WNT/β-catenin pathway has many interactions with other pathways involved in EMT. For example, it cooperates with TGF-β signaling to induce EMT in palate medial-edge epithelial cells [11, 85] and increases HIF-1α expression in prostate and liver cancer, which in turn results in EMT [86–90]. In glioma there is ample evidence for the relevance of the WNT/β-catenin pathway in the mesenchymal transition. First, expression of pathway components correlates to survival in glioma patients [91–93]. Second, WNT/β-catenin signaling has been shown to promote glioma cell proliferation, migration, invasion and radio- and chemoresistance [94–104]. Most importantly, however, EMT-mediated chemoresistance can be reversed in glioblastoma stem cells by treatment with secreted Frizzled-related protein (sFRP4), which functions as a WNT antagonist [105, 106]. A recent study demonstrated that the role of WNT/β-catenin signaling in pediatric HGG, in contrast to adult GBM, is very limited [107].

Besides the canonical WNT/β-catenin pathway, two non-canonical WNT signaling pathways have been identified; the planar cell polarity (PCP) and WNT/Ca²⁺ pathways [108, 109]. Although not extensively studied, components of these
pathways, most importantly WNT5A, have been shown to be involved in the induction of EMT in several types of cancer [110–114]. Both non-canonical WNT pathways have been shown to play a role in adult glioma, where they increase stemness and invasive properties of glioma cells [109, 115–122]. Data on the role of non-canonical WNT signaling in pHGG and DIPG has not been published to this day.

PI3K/AKT signaling in the mesenchymal transition

Activation of well-known receptor tyrosine kinases (RTK), such as the EGF, FGF and PDGF receptors, as well as G-protein coupled receptors (GPCR), is known to induce EMT via activation of the canonical PI3K/AKT and RAS/MAPK pathways. The role of the PI3K/AKT pathway in EMT is well established; after activation of the pathway, AKT inhibits GSK3β by phosphorylating serine 9. This in turn prevents GSK3β from phosphorylating SNAIL or SLUG, thus inhibiting their ubiquitination and subsequent proteasomal degradation [123, 124]. Via this mechanism, activation of the PI3K/AKT pathway causes stabilization of SNAIL family proteins, thereby inducing EMT [11].

In addition, activation of the PI3K/AKT pathway induces the transcription of ZEB1 by reducing GSK3β-mediated phosphorylation of β-catenin, thereby stabilizing the protein and inducing ZEB1 transcription via a β-catenin/TCF4 complex [125, 126]. Finally, AKT-mediated TWIST1 phosphorylation promotes EMT, as for example in the case of breast cancer metastasis, by modulating its transcriptional target TGF-β2, leading to enhanced TGF-β receptor signaling. This signaling pathway in turn maintains hyperactive phosphoinositide 3-kinase (PI3K)/AKT signaling, resulting in induction of EMT [127]. The PI3K/AKT pathway, which is commonly activated in malignant cells, has been shown to induce EMT in several tumor types. In certain types of cancer, inhibition of the overactive PI3K/AKT signaling resulted in a decrease of mesenchymal characteristics and (re-)sensitization of cancer cells to chemo- and radiotherapy [128–131].

There are several EMT pathways that cross talk with the PI3K/AKT/GSK3β pathway in glioma, for example the HIF-1α and the WNT/β-catenin pathways [132–135]. According to aberrant activation of the PI3K/AKT pathway [136]. In line with this finding, PI3K/mTOR kinase inhibitors provide a promising glioma therapy, as those drugs sensitize tumor cells to radiation and chemotherapy [137]. In pediatric HGG and DIPG, activating mutations in genes encoding PI3K are found in 15–26% of patients [138–140], which may contribute to the mesenchymal transition in these tumors.

RAS/MAPK signaling in the mesenchymal transition

Activation of RTKs also leads to signaling via the RAS/MAPK pathway [141]. Within this cascade, ERK1/2 phosphorylation and subsequent nuclear translocation leads to an increase in the transcription of SNAIL and SLUG and regulators of cell invasion and motility through activation of RHO-GTPases [11, 142]. Additionally, MAPK signaling leads to increased phosphorylation and stabilization of TWIST1 [143], as well as increased transcription of TGF-β [144, 145]. Oncogenic mutations in the RAS/MAPK pathway, such as loss of NF1, a negative regulator of RAS, or activating mutations in BRAF and KRAS are common in cancer and have been shown to induce EMT [143, 146–151]. In these tumors, treatment with MEK inhibitors resulted in a reduction in EMT-associated proteins and even signs of induction of MET [145, 152–154]. In pediatric low-grade glioma (LGG), activating mutations of BRAF are common, and confer a worse prognosis [155]. In contrast, mutations in the RAS/MAPK pathway are rare in high-grade glioma, although loss of NF1 is sometimes found [136]. Yet, activation of the MAPK pathway is common, because of amplifications or mutations in EGFR and other RTKs [156]. In pediatric HGG, mutations in the RAS/MAPK pathway and loss of NF1 are even less frequent, compared to the adult disease with the lowest prevalence found in DIPG [138–140, 157]. Additionally, activating EGFR mutations are not found in pediatric HGG, although amplification of the EGFR and PDGFRα genes has been described [38, 49, 50, 139]. The significance of these findings in pediatric HGG is unclear; trials with MEK inhibitors in pediatric HGG and LGG give promising results [158], whereas a trial using the multi-kinase inhibitor sorafenib in pediatric low-grade glioma patients resulted in paradoxical progression of BRAF wild type tumors [159].

The TAM family of receptor tyrosine kinases

Among the receptor tyrosine kinases, the TAM family, consisting of TYRO3, AXL and MERTK, plays a particular role in the induction of EMT. TYRO3 and MERTK can both be activated by binding of their endogenous ligands protein S and Gas6, whereas AXL can only bind Gas6 [160]. Additionally, AXL can form heterodimers with other RTKs, such as the EGF and PDGF receptors, thereby being transactivated by binding of their respective ligands [161]. Activation of TAM receptors triggers intracellular signaling cascades that have resulted in EMT in a large number of cancer types. Consequently, TAM signaling has been proven to be involved in migration of cancer cells in hepatocellular, colorectal and breast cancer, and resistance to chemo- and targeted therapy in breast cancer [161–173].
In glioblastoma, both AXL and MERTK have been identified as potential therapeutic targets and causes of treatment resistance. Inhibition of AXL and/or MERTK leads to diminished proliferation, migration and invasion of glioma cells, as well as sensitization of glioma cells to chemotherapy [174–180]. Although specific studies addressing the biological role of the TAM RTKs in pediatric HGG and DIPG are not available, overexpression of both AXL and MERTK has been described, and AXL has been shown to be activated in cultured DIPG cells [180, 181].

**The JAK/STAT pathway in the mesenchymal transition**

Besides the PI3K/AKT and RAS/MAPK pathway, a third pathway can be activated after engagement of cell surface receptors by their ligands; the JAK/STAT pathway. Although commonly associated with GPCRs, RTKs are also capable of initiating signaling along the JAK/STAT pathway. In this pathway, receptor-associated Janus kinases (JAKs) phosphorylate and activate signal transducer and activator of transcription (STAT) proteins. Upon phosphorylation, STATs form homo- or heterodimers that can function as transcription factors [182]. Within this family of proteins, STAT3 is known to induce EMT through upregulating the transcription of *SNAIL1*, *ZEB1*, *HIF-1α*, and most importantly, *TWIST* [183–187]. Under normal circumstances, activity of the JAK/STAT3/TWIST pathway is involved in neurogenesis and astrogliogenesis [188]. In cancer, however, aberrant activation of the pathway can induce EMT and thereby chemoresistance, as has been described, for example, in colorectal [184], breast [183] and ovarian cancer [189]. Based on these findings, clinical trials utilizing SMO inhibitors are currently ongoing for breast cancer [190, 191], ovarian cancer [189] and bile duct cancer [192]. In adult glioma, STAT3 activation is associated with increased tumor growth, angiogenesis, therapy resistance and worse patient outcome [12]. STAT3 activation enhances glioma stem cell self-renewal, as well as invasion and migration of glioma cells. Furthermore, inhibition of STAT3 enhances the response of glioma cells to temozolomide and radiation [193–196]. This suggests that inhibiting the JAK/STAT3 pathway may be an effective therapeutic strategy for high-grade glioma. The same might be true for pediatric HGG and DIPG, as overexpression of STAT3 has been reported as one of the hallmarks of the mesenchymal subtype in these tumors [38]. Additionally, overexpression of interleukin-4 and -13 receptors, known to induce JAK/STAT signaling, has been described in pediatric high-grade gliomas and DIPG [197–200].

**The sonic hedgehog pathway in the mesenchymal transition**

Sonic hedgehog (SHH) is a soluble glycoprotein that can bind to the transmembrane receptor Patched1 (PTCH1), thereby inducing phosphorylation and stabilization of another transmembrane receptor, Smoothened (SMO). Activated SMO phosphorylates a variety of intracellular signaling molecules that eventually lead to increased activity of the GLI family of transcription factors [201, 202]. The GLI proteins, in turn, induce the expression of genes associated with EMT, such as *SNAI1, SNAI2, ZEB1, ZEB2* and *TWIST* [203, 204]. In the signaling cascade following activation of Smoothened there is a large amount of crosstalk with other pathways involved in EMT, such as the NOTCH, WNT/β-catenin, TGF-β and EGFR pathways [205, 206]. Aberrant activation of the Hedgehog pathway is involved in EMT in various malignancies, such as breast cancer and gastric cancer [207, 208]. In high-grade glioma cells, it has been shown to be involved in invasion, migration, proliferation and maintenance of stem cell properties [205, 209]. Moreover, high activity of the hedgehog pathway is correlated to worse outcome in patients suffering from HGG [210].

Inhibition of SMO represents a promising strategy to overcome therapy resistance in HGG; the Smoothened inhibitor cyclopamine has been shown to induce radiosensitization in glioblastoma cells and Erismodegib, another SMO inhibitor, was capable of inhibiting self-renewal and EMT in glioblastoma initiating cells [211, 212]. Additionally, chemical inhibition of the hedgehog pathway could sensitize glioma stem cells to temozolomide [213].

The hedgehog pathway has been found to be active in DIPG cells, where it plays a crucial role in self-renewal of malignant cells [214]. Its connection with the mesenchymal transition described in DIPG has not been studied yet.

**The NOTCH pathway in the mesenchymal transition**

Mammalian cells express four transmembrane NOTCH receptors, NOTCH 1–4, and five canonical transmembrane ligands: Delta-like 1, Delta-like 3, Delta-like 4, Jagged-1 and Jagged-2 [215]. When a NOTCH ligand binds to two adjacent NOTCH receptors of neighboring cells, NOTCH will be cleaved into an extracellular and an intracellular domain, by a dysintegrin and metalloproteinase domain-containing protein (ADAM) 10 or ADAM 17 and γ-secretase (Fig. 3). The active intracellular domain of NOTCH translocates to the nucleus, binds to C-protein binding factor 1/Suppressor of Hairless/Lag-1 (CSL), forming a transcription activator complex. The NOTCH-CSL complex induces transcription of numerous genes associated with differentiation and/or survival including a variety of genes associated with EMT, such as *SNAI1, SNAI2, ZEB1, FN1* and *PDGFRs*. 

---

Springer
Furthermore, there is evidence of extensive crosstalk between the TGF-β and NOTCH pathways in the process of EMT [219, 220]. As with many other factors involved in EMT, the normal function of the NOTCH pathway seems to be in embryonic development and stem cell maintenance [219]. However, the NOTCH pathway is commonly dysregulated in cancer cells, where it can serve as both a tumor suppressor and as an oncogene, dependent on the cancer type [219]. NOTCH signaling induces proliferation, migration and invasion of glioma cells and is required for maintenance of both normal neural stem cells and glioma stem cells [221–224]. In these stem cells, NOTCH signaling induces self-renewal and inhibits differentiation [217, 225, 226]. Consequently, high levels of NOTCH signaling are associated with a poor prognosis in patients suffering from GBM [224]. γ-Secretase inhibitors have been shown to reduce proliferation and signs of stemness in glioma cells and to sensitize them to chemotherapy and radiation [227–231]. Moreover, these inhibitors have been shown to reduce proliferation of DIPG cells in vitro and to increase their radiosensitivity [232]. Although the role of NOTCH in EMT in pediatric HGG and DIPG has not been addressed yet, these results make it an interesting target for future translational research.

**Role of hypoxia in the mesenchymal transition**

Another external factor, other than growth factors and cytokines that is capable of inducing mesenchymal transition is hypoxia. Exposure of tumor cells to hypoxia induces stabilization of hypoxia-inducible factor 1α (HIF-1α), which dimerizes with HIF-1β to form a transcription factor complex (Fig. 3). Activity of this complex results in expression of genes involved in EMT, including NOTCH, CTNNB1 (β-catenin), SNAIL1 and TWIST [233–239]. Additionally, the expression of HIF-2α (EPAS1) is associated with ZEB2-induced EMT in breast cancer [240].

Besides EMT, these hypoxia-inducible factors induce expression of genes responsible for stem cell properties, such as self-renewal and multipotency via mechanisms common to EMT, such as the NOTCH signaling pathway [241]. Furthermore, in many different cancer types, hypoxia-inducible factors are involved in proliferation, migration and invasion, reinforcing the hypothesis that hypoxia can initiate EMT in cancer cells [235, 237–239, 242, 243]. In glioblastoma cells specifically, hypoxia induces and maintains stem cell characteristics, and HIF-1α has been shown to be involved in proliferation, migration invasion and radio- and chemoresistance [238, 239, 244–252]. In both adult and pediatric HGG, overexpression of HIF-2α has been found, which negatively correlated with patient survival [247, 253], although data on HIF-1α in pediatric HGG is lacking.

**The cadherin switch**

The ultimate result of activation of the EMT-related signaling pathways described above is the so-called cadherin switch [254–257] (Fig. 1). Cadherins are a large family of transmembrane glycoproteins involved in intercellular adhesions and signaling. Epithelial cells normally express E-cadherin, the expression of which is tightly regulated. The...
SNAIL and ZEB families of transcription factors bind to an E-Box motif in the promoter region of the CDH1 gene, causing its transcriptional repression [11, 23, 41]. Simultaneously, they induce an upregulation of other cadherins, mostly CDH2 and/or CDH4 [11]. Other transcription factors involved in the mesenchymal transition, such as TCF3 (E12/E47), and the TWIST and SIX families of transcription factors, induce similar changes in cadherin expression via different mechanisms than described above [11, 254–257]. Loss of expression of E-cadherin (CDH1), and induction of expression of N- or R-cadherin (CDH2 or CDH4), triggers a series of events that allows cancer cells to become less dependent of their micro-environment, thereby promoting cell migration, invasion and metastasis [254–257]. Additionally, the intracellular domain of E-cadherin binds β-catenin (CTNNB1), and loss of its expression causes β-catenin to locate to the nucleus where it acts as a transcription factor for various genes associated with the mesenchymal phenotype [257, 258]. The broad range of functions attributed to cadherins also includes profound influences on several signal transduction pathways, such as the PI3K/AKT, MAPK and NF-κB pathways, both directly and through modulation of receptor tyrosine kinases such as FGFR, EGFR, PDGFR and integrin-linked kinases [259–263].

In adult glioblastoma (GBM), loss of E-cadherin expression and concurrent increase in either N- or R-cadherin expression is related to a more mesenchymal phenotype, tumor invasiveness and worse overall survival [254, 260, 264–266]. Furthermore, the mesenchymal phenotype seems to be responsible for an increased resistance to chemotherapy and radiation, two important modalities in GBM treatment [15]. To this date, the role of cadherins in pediatric high-grade glioma has not been sufficiently addressed to determine their precise role in the mesenchymal transition in these tumors.

Discussion

Over the past years, the mesenchymal transition has received considerable attention in the field of oncology, due to its relationship with invasion, metastasis and therapy resistance of cancer cells. Components of the mesenchymal transition have often been put forward as therapeutic targets and/or therapy-sensitizing agents, not in the least in the treatment of adult glioblastoma. However, little research is available on the role of the mesenchymal transition in pediatric high-grade glioma and diffuse intrinsic pontine glioma. The therapy resistance and diffusely infiltrative nature that these tumors often possess imply that mesenchymal gene expression may play a larger role in their biology than is known so far. We have reviewed current knowledge about the major signal transduction pathways involved in initiation and maintenance of the mesenchymal transition in cancer in general, and high-grade glioma in particular.

When comparing published RNA expression datasets available from normal brain tissue [267], adult GBM [268], pediatric HGG [49] and DIPG [48], major differences can be found in the expression of certain key components of the mesenchymal transition (Fig. 4). Most prominently, expression of the transcription factor ZEB1 is higher in pHGG and DIPG compared to adult GBM, whereas expression of SIX1 is upregulated in both pHGG and adult GBM, but not in DIPG. This is in contrast with other transcription factors, such as TCF3, the expression of which was equal in all three tumor types. Expression of upstream regulators of transcription factors involved in the mesenchymal transition revealed further differences between pHGG, DIPG and adult GBM. Most strikingly, the expression of EGFR and ERBB2—two commonly targeted RTKs in the treatment of glioma—was much higher in adult GBM compared to pHGG and DIPG. Combined with the observation from previous studies that EGFR mutations are rarely to never found in pediatric HGG and DIPG, these data suggest that the role of EGFR signaling in pediatric gliomas is more limited than in the adult counterpart [38, 49, 50, 139]. On the contrary, the expression of Patched (PCHT1), an important component of the hedgehog pathway, was higher in DIPG than in supratentorial pHGG and adult GBM, possibly as a result of their different developmental origins [214]. Finally, in contrast to previous reports describing overexpression of HIF2A in both pediatric and adult HGG [247, 253], only adult GBM possessed HIF2A overexpression in the datasets we analyzed, whereas HIF1A was overexpressed in all three tumor types. Tables 1 and 2 present a brief overview of transcription factors and signaling pathways addressed in this review and compare their relative importance in pHGG, DIPG and adult GBM, as far as current knowledge allows for.

The differences in mechanisms of mesenchymal transition employed by pHGG and DIPG as compared to adult GBM will provide researchers with important clues in the identification of therapeutic targets and the design of novel therapeutic strategies to overcome therapy resistance and metastasis in these hard-to-treat brain tumors. With the currently available knowledge, several promising therapeutic targets for interfering with the mesenchymal transition in pHGG and DIPG can already be identified. With the development of selective ACVR1 inhibitors, tumors harbouring activating ACVR1 mutations and a mesenchymal phenotype can potentially be chemotherapycs and radio-sensitized using these compounds [269]. Furthermore, tumors possessing a mesenchymal phenotype related to mutations in the PI3K and/or MAPK pathway can potentially be sensitized to therapy by the use of PI3K or MEK inhibitors, many of which are already clinically approved for other indications. Also, considering the perceived importance of the hedgehog pathway
in the development and progression of DIPG, currently available Smoothened inhibitors may be used to interfere with the mesenchymal transition in this type of cancer. Within the paradigm of the mesenchymal transition, these drugs would only serve as therapy sensitizers, and should therefore always be combined with other cytotoxic therapeutics or radiotherapy. Finally, over the past years, it has become clear that a large part of pediatric HGG and DIPG are driven by mutations in genes encoding the Histone 3 protein. These mutations either induce a K27M or G34R/V substitution in the N-terminal end of the Histone 3 protein, thereby preventing histone methyltransferases from methylating H3K27 or H3K36 and causing a global epigenetic shift [3–7, 270]. This hypomethylation of Histone 3 at the K27 or K36 residues causes genome-wide changes in gene expression. Of these, the gene expression changes induced by the H3K27M mutation have been extensively investigated [270–273]. Despite this thorough research, the influence of the Histone 3 mutations on the expression of genes involved in the mesenchymal transition has not been specifically addressed yet. Given the observation that differences in expression of mesenchymal genes exist between DIPG carrying a H3.1 or H3.3 K27M mutation, it is not unlikely that the epigenetic shift induced by these mutations

![Fig. 4](image-url) RNA expression levels of genes involved in the (epithelial-to-) mesenchymal transition that show a strong differential expression between normal brain tissue [267], adult GBM [268], pediatric HGG [49] and DIPG [48]. Source: R2 (http://r2.amc.nl). Blue stars indicate significant differences \((p < 0.01)\) compared to adult GBM, red stars indicate significant differences \((p < 0.01)\) compared to normal brain tissue.

| Transcription factors | Relevance in adult GBM, pediatric HGG and DIPG |
|-----------------------|-----------------------------------------------|
| SNAIL family          | Proven important role in mesenchymal transition in adult GBM, suggested to play a role in DIPG, insufficient data on pediatric HGG |
| ZEB family            | Proven role in mesenchymal transition in adult GBM and pediatric HGG, insufficient data on DIPG. The presence of a PDGFRα-ZEB1 axis and expression levels of ZEB1/2 suggest important role in pediatric HGG and DIPG |
| TWIST family          | Proven important role in mesenchymal transition in adult GBM, no available data on pediatric HGG and DIPG |
| SIX family            | Proven role in mesenchymal transition in adult HGG, no available data on pediatric HGG and DIPG. Expression data suggest inferior role in DIPG compared to adult and pediatric supratentorial HGG |
is capable of influencing or even inducing the mesenchymal transition in these tumors [38]. These preliminary data warrant further investigation of the connection between Histone 3 mutations, the resulting changes in histone methylation, and the mesenchymal transition in these tumors.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Gajjar A, Packer RJ, Foreman NK, Cohen K, Haas-Kogan D, Merchant TE (2013) Children's Oncology Group’s 2013 blueprint for research: central nervous system tumors. Pediatr Blood Cancer 60:1022–1026
2. van Zanten SEMV et al (2017) External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. J Neurooncol 134:231–240
3. Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer 14:651–661
4. Khuong-Quang DA et al (2012) K27 M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439–447
5. Schwartzentruber J et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231
6. Sturm D et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437
7. Wu G et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251–253
8. Hamisch C, Kickinggereder P, Fischer M, Simon T, Ruge MI (2017) Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. J Neurosurg Pediatr 20:261–268
9. Jakacki RJ et al (2016) Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study. Neuro Oncol 18:1442–1450
10. Donaldson SS, Laningham F, Fisher PG (2006) Advances toward an understanding of brainstem gliomas. J Clin Oncol 24:1266–1272
11. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196
12. Carro MS et al (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318–325
13. Raggi C, Mousa HS, Correnti M, Sica A, Invernizzi P (2016) Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene 35:671–682
14. Phillips HS et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173
15. Ducray F et al (2010) An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Mol Cancer 9:234
16. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, de Garcia HA (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2:84–89
17. Dong C et al (2013) Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 32:1351–1362
18. Ghahhari NM, Babashah S (2015) Interplay between microRNAs and WNT/beta-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer 51:1638–1649
19. Kauflhold S, Bonavida B (2014) Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res 33:62
20. Wang H et al (2014) Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cispatin-resistant lung cancer cells through AKT/beta-catenin/ Snail signaling pathway. Eur J Pharmacol 723:156–166
21. Alves CC, Carneiro F, Hoeller H, Becker KF (2009) Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 14:3035–3050 (Landmark, Ed)
22. Fenouille N et al (2012) The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 7:e40378
23. Villagrana P et al (2012) Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene 31:4022–4033
24. Lin Y, Dong C, Zhou BP (2014) Epigenetic regulation of EMT and invasion in mice and humans. Oncogene 35:5641–5652
25. Satelli A, Li S (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68:3033–3046
26. Satelli A, Li S (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68:3033–3046
27. Liu ZC et al (2014) Snail regulated by PKC/GSK-3beta pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells. Cell Tissue Res 358:491–502
28. Sun M, Song L, Zhou T, Gillespie GY, Jope RS (2011) The role of DDX3 in regulating Snail. Biochim Biophys Acta 1813:438–447
29. Hahn S, Jackstadt R, Siemens H, Hunten S, Hermeking H (2011) SNAI1 is involved in the proliferation and invasion of gliomas. BMC Cancer 11:3079–3095
30. Wang Y, Shi J, Chai K, Ying X, Zhou BP (2013) The role of DDX3 in regulating Snail. Biochim Biophys Acta 25:724–732
31. Yang HW, Menon LG, Black PM, Carroll RS, Johnson MD (2010) SNAI2/Slug promotes growth and invasion in human gliomas. BMC Cancer 10:301
32. Hill L, Browne G, Tulchinsky E (2013) ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer 132:745–754
33. Shimono Y et al (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138:592–603
34. Wellner U et al (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487–1495
35. Cieply B, Farris J, Denvir J, Ford HL, Frisch SM (2013) Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Res 73:6299–6309
36. Siebhzuhrufl FA et al (2013) The ZEB1 pathway links glioblastoma initiation, invasion and chemoresisistance. EMBO Mol Med 5:1196–1212
37. Kahlert UD et al (2015) ZEB1 promotes invasion in human fetal neural stem cells and hypoxic glioma neurospheres. Brain Pathol 25:724–732
38. Zhang L et al (2016) SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Oncogene 35:5641–5652
39. Paugh BS et al (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29:3999–4006
40. Paugh BS et al (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061–3068
41. Wu G et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46:444–450
42. Qi S et al (2012) ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One 7:e38842
43. Yeasmin S et al (2011) Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition. Int J Cancer 128:94–104
44. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688
45. Li X et al (2011) miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9:824–833
46. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28:2940–2947
47. Nordfors K et al (2015) Twist predicts poor outcome of patients with astrocytic glioma. J Clin Pathol 68:905–912
48. Krossa S, Schmitt AD, Hattermann K, Fritsch J, Scheidig AJ, Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget 2:1028–1042
49. Iwanaga R et al (2012) Expression of Six1 in luminal breast cancer predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res 14:R100
60. Li Z et al (2014) Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion. Int J Clin Exp Pathol 7:631–639
61. Micalizzi DS et al (2009) The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling. J Clin Invest 119:2678–2690
62. Xu H, Zhang Y, Altomare D, Peña MM, Wan F, Pirisi L, Creek KE (2014) Six1 promotes epithelial-mesenchymal transition and malignant conversion in human papillomavirus type 16-immortalized human keratinocytes. Carcinogenesis 35:1379–1388
63. Ono H et al (2012) SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. Oncogene 31:4923–4934
64. McCoy EL, Iwanaaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL (2009) Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest 119:2663–2677
65. Tian T, Li A, Lu H, Luo R, Zhang M, Li Z (2015) Six1 promotes glioblastoma cell proliferation and invasion by upregulation of connective tissue growth factor. Am J Cancer Res 5:1823–1830
66. Auvergne RM et al (2013) Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep 3:2127–2141
67. Massague J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19:2783–2810
68. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL (2000) Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275:36803–36810
69. Derynick R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577–584
70. Buczkwicz P et al (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46:451–456
71. Taylor KR et al (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46:457–461
72. Bramlage CP et al (2010) Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis. BMC Nephrol 11:31
73. Fontehassari AM et al (2014) Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 46:462–466
74. Meng XM, Chung AC, Lan HY (2013) Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond) 124:243–254
75. Adler PN, Krasnow RE, Liu J (1997) Tissue polarity points from drosophila functions as a Wingless receptor. Nature 382:225–230
76. Hey PJ et al (1998) Cloning of a novel member of the low-density lipoprotein receptor family gene. Gene 216:103–111
77. Brown SD et al (1998) Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem Biophys Res Commun 248:879–888
78. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797–3804
79. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A (1998) Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 17:1371–1384
80. Fagotto F, Gluck U, Gumbiner BM (1998) Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 8:181–190
81. Yokoya F, Imamoto N, Tachibana T, Yoneda Y (1999) beta-catenin can be transported into the nucleus in a Ran-unassisted manner. Mol Biol Cell 10:1119–1131
82. Ille F, Sommer L (2005) Wnt signaling: multiple functions in neural development. Cell Mol Life Sci 62:1100–1108
83. Nuße R (1999) WNT targets. Repression and activation. Trends Genet 15:1–3
84. Nawashad A, Medici D, Liu CC, Hay ED (2007) TGFbeta3 inhibits its E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4-LEF1 transcription complex. J Cell Sci 120:1646–1653
85. Liu C et al (2011) Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 34:962–973
86. Rossi M et al (2011) beta-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther 11:753–761
87. Liu C et al (2011) Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med 11:105–112
88. Zhang Q et al (2013) Wnt/beta-catenin signaling enhances cellular carcinoma via crosstalk with hif-1alpha signaling. Cancer 29:377–382
89. Chen L et al (2014) A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. Oncol Rep 31:1573–1580
90. Zhang Q et al (2013) Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 34:962-973
91. Liu C et al (2011) Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med 11:105–112
92. Zhang LY et al (2010) Reduced beta-catenin expression is associated with good prognosis in Astrocytoma. J Pathol Oncol Res 6:105–112
93. Kamino M et al (2011) Wnt-5a signaling is correlated with invasive activity in human glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett 325:42–53
94. Sareddy GR, Panigrahi M, Challa S, Mahadevan A, Babu PP (2011) beta-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther 11:753–761
95. Zhao JH, Luo Y, Jiang YG, He DL, Wu CT (2011) Knockdown of beta-Catenin through shRNA causes a reversal of EMT and metastatic phenotypes induced by HIF-1alpha. Cancer Invest 29:377–382
96. Zhao J et al (2013) Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep 3:2127–2141
97. Taylor KR et al (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46:457–461
98. Liu C et al (2011) Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med 11:105–112
99. Zhang Q et al (2013) Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 34:962–973
100. Rampazzo E et al (2013) Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis 4:e500
101. Kaur N, Chettiar S, Rathod S, Rath P, Muzumdar D, Shaikh ML, Shiras A (2013) Wnt3a mediated activation of Wnt/beta-catenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci 54:44–57

102. Wang K, Park JO, Zhang M (2013) Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and beta-catenin. J Gene Med 15:42–50

103. Kim Y et al (2012) Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 92:466–473

104. Zhukova N et al (2014) WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun 2:174

105. Bhuvanakshmi G, Arfuso F, Millward M, Dharmarajan A, Warrier S (2015) Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties. PLoS One 10:e0127517

106. Warrier S, Balu SK, Kumar AP, Millward M, Dharmarajan A (2013) Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res 21:93–102

107. Wiese M et al (2017) The beta-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner. Oncotarget 8:27300–27313

108. Komiya Y, Habas R (2008) Wnt signal transduction pathways. Organogenesis 4:68–75

109. Grumolato L et al (2010) Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 24:2517–2530

110. Bo H, Zhang S, Gao L, Chen Y, Zhang J, Chang X, Zhu M (2013) Upregulation of Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells. BMC Cancer 13:496

111. Ren D, Minami Y, Nishita M (2011) Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes Cells 16:304–315

112. Asano T et al (2017) Clinical implication of Frizzled 2 expression regulating the lncRNA MALAT1. Oncogene 35:12–21

113. Wald JH et al (2017) Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene 36:5158–5167

114. Yu JM, Jun ES, Jung JS, Suh SY, Han JY, Kim JY, Kim KW, Jung JS (2007) Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett 257:172–181

115. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6:931–940

116. Bachelder RE, Yoon SO, Franci C, De Herreros AG, Mercurio AM (2005) Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 168:29–33

117. Wu K et al (2012) PI3 K/Akt to GSK3beta/beta-catenin signaling cascade coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 transcription. Cell Signal 24:2273–2282

118. Peng C et al (2015) The 14–3-3sigma/GSK3beta/beta-catenin/ ZEB1 regulatory loop modulates chemo-sensitivity in human tongue cancer. Oncotarget 6:20177–20189

119. Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D, Ruegg C, Hemmings BA (2012) Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3 K/Akt and TGF-beta signaling axes. Cancer Discov 2:248–259

120. Wang H et al (2013) Epithelial-mesenchymal transition (EMT) induced by TNF-alpha requires Akt/GSK-3beta-mediated stabilization of snail in colorectal cancer. PLoS One 8:e56664

121. Maseki S et al (2012) Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK3beta/snaill signaling pathway. Br J Cancer 106:1196–1204

122. Jiao M, Nan KJ (2012) Activation of PI3 kinase/Akt/HIF-1alpha pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 40:461–468

123. Chang L, Graham PH, Hao J, Ni J, Buccig J, Cozzi PJ, Kearsley JH, Li Y (2013) Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3 K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 4:e875

124. Baryawno N, Sveinbjornsson B, Eksborg S, Chen CS, Kogner P, Johnsen JJ (2010) Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res 70:266–276

125. Blum R, Jacob-Hirsch J, Amarglio N, Rechavi G, Kroog Y (2005) Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 65:999–1006

126. Han L et al (2010) Inactivation of PI3 K/AKT signaling inhibits glioma cell growth through modulation of beta-catenin-mediated transcription. Brain Res 1366:9–17

127. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, Maity A (2006) Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol. Cancer 4:471–479

128. Kwak HJ et al (2011) Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 30:2433–2442

129. Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA (2014) Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3 K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 14:17
134. Robison NJ, Kieran MW (2012) Identification of novel biologic targets in the treatment of newly diagnosed diffuse intrinsic pontine glioma. In: 2012 ASCO annual meeting, vol 2, pp 625–628
135. Grill J, Puget S, Andreiullo F, Philippe C, MacConaill L, Kieran MW (2012) Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 58:489–491
136. Nguyen PT, Tsumetatsu T, Yanagisawa S, Kudo Y, Miyachi M, Kamata N, Takata T (2013) The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer 109:2248–2258
137. Lassaletta A et al (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35:2934–2941
138. Lo HW (2010) Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 10:840–848
139. Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer 14:651–661
140. Truong AY, Nicolaudes TP (2015) Targeted therapy for MAPK alterations in pediatric gliomas. Brain Disord, Ther Suppl, p 2
141. Karajannis MA et al (2014) Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol 16:1408–1416
142. Lingir RMA, Keating AK, Earp HS, Graham DK (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100:35–83
143. Meyer AS, Miller MA, Gertler FB, Launfenerbarg DA (2013) The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal 6:ra66
144. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Cichon MA, Szentpetery Z, Caley MP, Papadakis ES, Mackenzi IC, Brennan CH, O’Toole EA (2014) The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in breast cancer stem/progenitor cells. Cancer Res 74:1878–1889
145. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavia B (2010) The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-kappaB/Snail/Slug pathway. Mol Cancer 10:164–175
146. Voon DC et al (2013) EMT-induced stemness and tumorigenicity of sunitinib response in glioblastoma cell lines. Exp Cell Res 327:1–10
209. Takezaki T, Hide T, Takanaga H, Nakamura H, Kuratsu J, Kondo T (2011) Essential role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer Sci 102:1306–1312

210. Yan GN et al (2014) Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway. J Pathol 234:11–22

211. Alqudah MA, Agarwal S, Al-Keilani MS, Sibenaller ZA, Ryken M, Espinoza I, Miele L (2013) Deadly crosstalk: Notch signaling is upregulated in glioma and is associated with antiangiogenic treatment resistance in glioblastomas. Stem Cells 31:72–83

212. Fu J, Rodova M, Nanta R, Meeker D, Van Veldhuizen PJ, Srivastava RK, Shankar S (2013) Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem Cells Dev 22:1319–1328

213. Ulasov IV, Nandi S, Poulsen HS, Stockhausen MT, Alqudah MA, Agarwal S, Al-Keilani MS, Sibenaller ZA, Ryken M, Espinoza I, Miele L (2013) Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem Cells Dev 22:1319–1328

214. Chen X, Xiao W, Liu X, Zeng M, Luo D, Wang J, Li J, Post M (2011) Mouse snail is a target gene for HIF. Mol Cancer Res 9:234–245

215. Mahase S, Rattenni RN, Wesseling P, Leenders W, Baldotto C, Jain R, Zagg R, Zagg D (2015) HIF-mediated mechanisms associated with antiangiogenic treatment resistance in glioblastomas. J Am Pathol 187:940–953

216. Kim SW et al (2015) Genome-wide transcript profiling reveals novel breast cancer-associated intrinsic sense RNAs. PLoS One 10:e0120296

217. Keith B, Simon MC (2007) Hypoxia inducible factors, stem cells and cancer. Cell 129:465–472

218. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8:3274–3284

219. Nakamura H, Kuratsu J, Takezaki T, Hide T, Takanaga H, Wang J, Wang XF, White RR, Rich JN, Sullenger BA (2010) Notch promotes radiation sensitivity of glioma stem cells. Stem Cells 28:17–28

220. Miele L (2006) Notch signaling. Clin Cancer Res 12:1074–1079

221. Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS (2011) Inhibition of Sonic hedgehog pathway blockades CD133(+) glioma stem cells to temozolomide therapy. Mol Med 17:103–112

222. Hovinga KE et al (2010) Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28:1019–1029

223. Hsu CY, Wang J, Kishimoto T, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA (2010) Notch promotes radioreistance of glioma stem cells. Stem Cells 28:17–28

224. Alqudah MA, Agarwal S, Al-Keilani MS, Sibenaller ZA, Ryken M, Espinoza I, Miele L (2013) Deadly crosstalk: Notch signaling is upregulated in glioma and is associated with antiangiogenic treatment resistance in glioblastomas. Stem Cells 31:72–83

225. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8:3274–3284

226. Cenciarelli C et al (2014) PDGF receptor alpha inhibition induces transdifferentiation switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem Cells Dev 22:1319–1328

227. Cenciarelli C et al (2014) PDGF receptor alpha inhibition induces transdifferentiation switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem Cells Dev 22:1319–1328

228. Gilbert CA, Daou MC, Moser RP, Ross AH (2010) Gamma-secretase inhibitors enhance temozolomide treatment of human glioblastomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 70:6870–6879

229. Nakamura H, Kuratsu J, Takezaki T, Hide T, Takanaga H, Wang J, Wang XF, White RR, Rich JN, Sullenger BA (2010) Notch promotes radiation sensitivity of glioma stem cells. Stem Cells 28:17–28
HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 9:133

Shen SH, Kwan AL, Chen YY, Wang ZX (2013) Effect of silencing HIF-1alpha on proliferation, invasion and migration of glioblastoma U87 cells. Neuronal 34:365–371

Gillespie DL, Wang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL (2007) Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 13:2441–2448

Luo Z et al (2015) Silencing of HIF-1alpha enhances the radiation sensitivity of human glioma growth in vitro and in vivo. Neuropharmacology 89:168–174

Khatua S et al (2003) Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 63:1865–1870

Appolloni I, Barilari M, Caviglia S, Gambini E, Reisoli E, Malatesta P (2015) A cadherin switch underlies malignancy in high-grade gliomas. Oncogene 34:1991–2002

Perez-Moreno M, Fuchs E (2006) Catenins: keeping cells from getting their signals crossed. Dev Cell 11:601–612

Perez-Moreno M, Jamora C, Fuchs E (2003) Sticky business: orchestrating cellular signals at adherens junctions. Cell 112:535–548

Schmalhofer O, Brabletz S, Brabletz T (2009) E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28:151–166

Bienz M (2005) beta-Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 15:R64–R67

Qian X et al (2014) N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene 33:3411–3421

Li et al (2013) Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and down-regulates E-cadherin via the NF-kappaB pathway. J Mol Histol 45:141–151

Velpula KK, Rehman AA, Chelluboina B, Dasari VR, Gondi CS, Rao JS, Veeravalli KK (2012) Glioma stem cell invasion through regulation of the interconnected ERK, integrin alpha6 and N-cadherin signaling pathway. Cell Signal 24:2076–2084

Zhao C, Li X, Su C, Li J, Cheng N, Ren S, Chen X, Zhou C (2015) High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients. Int J Clin Exp Pathol 8:3104–3109

Guo Y, Yin J, Zha L, Wang Z (2013) Clinicopathological significance of platelet-derived growth factor B, platelet-derived growth factor receptor-beta, and E-cadherin expression in gastric carcinoma. Contemp Oncol (Poln) 17:150–155

Wu W, Tian Y, Han H, Song Y, Li J, Zhang L (2013) The expressions of Wnt/beta-catenin pathway-related components in brainstem gliomas. Can J Neurol Sci 40:355–360

Wu W, Tian Y, Han H, Ma J, Song Y, Wang Y, Zhang L (2013) Expression of beta-catenin and E- and N-cadherin in human brainstem gliomas and clinicopathological correlations. Int J Neurosci 123:318–323

Lewis-Tuffin LI, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadias PZ (2010) Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One 5:e13665

Harris LW, Lockstone HE, Khaitovich P, Weickert CS, Webster MJ, Bahn S (2009) Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. BMC Med Genom 2:28

Reifenberger G et al (2014) Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer 135:1822–1831

Moheda AH et al (2014) Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem 57:7900–7915

Funato K, Major T, Lewis PW, Allis CD, Tabar V (2014) Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 346:1529–1533

Lewis PW et al (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340:857–861

Justin N et al (2016) Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat Commun 7:11316

Nagaraja S et al (2017) Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell 31(635–652):e6